XML 35 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization
 12 Months Ended
Dec. 31, 2023
Organization [Abstract]  
ORGANIZATION

1. ORGANIZATION

 

The consolidated financial statements include the financial statements of Aptorum Group Limited (the “Company”) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”.

 

The Company, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman Islands with limited liability.

 

The Company researches and develops life science and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies (collectively, “Aptorum Therapeutics Group”).

 

Below summarizes the list of the major subsidiaries consolidated as of December 31, 2023:

 

Name   Incorporation
date		   Ownership   Place of
incorporation		   Principle activities
Aptorum Therapeutics Limited (“ATL”)   June 30, 2016   100%   Cayman Islands   Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED   May 16, 2017   100%   Hong Kong   Provision of management services to its holding company and fellow subsidiaries
Aptorum Medical Limited   August 28, 2017   90%   Cayman Islands   Provision of medical clinic services
Paths Innovations Limited   April 15, 2019   100%   Cayman Islands   Investment holding company
Paths Diagnostics Pte. Limited   June 5, 2019   75%   Singapore   Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited   June 30, 2017   80%   Cayman Islands   Research and development of life science and biopharmaceutical products
Claves Life Sciences Limited   August 2, 2017   100%   Cayman Islands   Research and development of life science and biopharmaceutical products
Nativus Life Sciences Limited   July 7, 2017   100%   Cayman Islands   Research and development of life science and biopharmaceutical products
Videns Incorporation Limited   March 2, 2017   100%   Cayman Islands   Research and development of life science and biopharmaceutical products
Mios Pharmaceuticals Limited   March 6, 2018   97.93%   Cayman Islands   Research and development of life science and biopharmaceutical products
mTOR (Hong Kong) Limited   November 4, 2016   90%   Hong Kong   Research and development of life science and biopharmaceutical products
Scipio Life Sciences Limited   July 19, 2017   97.93%   Cayman Islands   Research and development of life science and biopharmaceutical products
Signate Life Sciences Limited   August 28, 2017   100%   Cayman Islands   Research and development of life science and biopharmaceutical products